APG808 vs dupilumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: IL-4R-alpha · full Chronic Obstructive Pulmonary Disease pipeline
APG808
Developed by Apogee Therapeutics under a licence from Paragon Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
dupilumab · Dupixent
Marketed by Regeneron Pharmaceuticals and partners
NCT03930732 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 939 participants, and its primary clinical endpoint was met: dupilumab significantly reduced moderate or severe COPD exacerbations over 52 weeks. The registry does not report the power or sample-size calculation needed to establish that the trial was adequately powered, so the evidence is graded as moderate rather than strong.
Next expected readout: July 2028 · NCT07587658 (registry estimate)
Reported efficacy
Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-week Treatment Period (Baseline (Day 1) to Week 52): Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-week Treatment Period (Baseline (Day 1) to Week 52): Placebo 1.295 Exacerbation per participant-year (95% CI 1.048 to 1.6) | Dupilumab 300 mg q2w 0.859 Exacerbation per participant-year (95% CI 0.699 to 1.057) (met)
Result source: NCT04456673
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | APG808 | dupilumab |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | —Not reported | 0.8 vs 1.0−0.2 vs placeboNCT039307321 other result
|
| Trough FEV1, change | —Not reported | —Not reported |
| SGRQ total, change | —Not reported | -9.7 vs -6.4−3.4 vs placeboNCT039307321 other result
|
| TDI focal score | —Not reported | —Not reported |
Moderate or severe exacerbations, annualised rate
- APG808
- —Not reported
- dupilumab
- 0.8 vs 1.0−0.2 vs placeboNCT03930732
1 other result
- 0.9 vs 1.3 NCT04456673
Trough FEV1, change
- APG808
- —Not reported
- dupilumab
- —Not reported
SGRQ total, change
- APG808
- —Not reported
- dupilumab
- -9.7 vs -6.4−3.4 vs placeboNCT03930732
1 other result
- -9.8 vs -6.4 NCT04456673
TDI focal score
- APG808
- —Not reported
- dupilumab
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
APG808: no structured comparison results are available for Chronic Obstructive Pulmonary Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. APG808: 0 of 4 rows · dupilumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | dupilumab |
|---|---|
| Dropout rate | 6%300 mg q2wa NCT03930732 · Phase 3 show 1 more result8.9%300 mg q2w NCT04456673 · Phase 3 |
| Discontinued due to AEs | 1.5%300 mg q2wa NCT03930732 · Phase 3 show 1 more result3%300 mg q2w NCT04456673 · Phase 3 |
| Serious AEs | 13.9%300 mg q2wa NCT03930732 · Phase 3 show 1 more result13.9%300 mg q2w NCT04456673 · Phase 3 |
| Most frequent reported AEs | 300 mg q2wa nasopharyngitis 9.6% (placebo 9.6%) headache 8.1% (placebo 7%) upper respiratory tract infection 7.9% (placebo 9.8%) NCT03930732 · Phase 3 show 1 more result300 mg q2w covid-19 9.6% (placebo 7.8%) headache 7.9% (placebo 6.3%) nasopharyngitis 6.8% (placebo 6%) NCT04456673 · Phase 3 |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
dupilumab
show 1 more result
show 31 more results
show 1 more result
show 1 more result
show 22 more results
show 7 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: APG808's landscape · dupilumab's landscape